|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eptifibatide#Contraindications]] |
| {{Eptifibatide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Contraindications==
| |
| | |
| | |
| | |
| Treatment with eptifibatide is '''contraindicated''' in patients with:
| |
| | |
| * A history of [[bleeding diathesis]], or evidence of active abnormal bleeding within the previous 30 days.
| |
| * Severe [[hypertension]] (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy.
| |
| * '''Major surgery''' within the preceding 6 weeks.
| |
| * History of [[stroke]] within 30 days or any history of [[hemorrhagic stroke]].
| |
| * Current or planned administration of another parenteral [[GP IIb/IIIa inhibitor]].
| |
| * Dependency on [[renal dialysis]].
| |
| * Known [[hypersensitivity]] to any component of the product.
| |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INTEGRILIN (EPTIFIBATIDE) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ad82e30-50d8-450c-8a2a-b4b507ed1ce2 | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |